• Logo
  • SBMUJournals

Topical Halometasone Reduces Acute Adverse Effects Induced by Pulsed Dye Laser for Treatment of Port Wine Stain Birthmarks

Lin Gao, Linhan Qian, Li Wang, Kai Li, Rong Yin, Yanting Wang, Hanmei Kang, Wenting Song, Gang Wang




Introduction: Pulsed dye laser (PDL) for treatment of port wine stain (PWS) usually causes some acute adverse effects, including pain, erythema, scabbing and swelling. This study aimed to determine whether topical halometasone can be used to reduce these acute adverse effects for post-PDL care of patients.
Methods: A total of 40 PWS subjects were enrolled in this study and randomly assigned into two regimens: PDL alone and PDL + halometasone. All subjects were given a single treatment of PDL with wavelength of 595 nm, fluence of 8.0~13.5 J/cm2, pulse duration of 0.45~20 ms (We mainly used purpuric pulse duration for PWS) and spot size of 7 mm. Subjects in the PDL + halometasone group received topical application of halometasone daily for 3 days. Subjects were followed-up on days 3, 7 and one month post-PDL to evaluate the reduction of adverse effects.
Results: Subjects in the PDL + halometasone group had significantly improved erythema and scab scores and had less erythema duration days as compared to those in the PDL alone group. Topical halometasone also showed a decrease in pain index among subjects, but was statistically insignificant. Topical halometasone did not affect the ultimate efficacy of PDL treatment for PWS.
Conclusion: Topical halometasone can significantly reduce acute adverse effects induced by PDL for treatment of PWS birthmarks, thus providing a safe and efficacious solution for post-PDL care of PWS patients.


Port wine stain; Pulsed dye laser; Halometasone; Adverse effects.


Mulliken JB, Young AR, Eds. Vascular Birthmarks-- Hemangiomas and Malformations. Philadelphia: W. B. Saunders Co; 1988.

Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics. 1976;58(2):218-222.

Pratt AG. Birthmarks in infants. AMA Arch Derm Syphilol. 1953;67(3):302-305. doi:10.1001/ archderm.1953.01540030065006.

Heller A, Rafman S, Zvagulis I, Pless I. Birth defects and psychosocial adjustment. Am J Dis Child. 1985;139(3):257- 263. doi:10.1001/archpedi.1985.02140050051021.

Malm M, Carlberg M. Port-wine stain--a surgical and psychological problem. Ann Plast Surg. 1988;20(6):512- 516.

Kalick SM. Toward an interdisciplinary psychology of appearances. Psychiatry. 1978;41(3):243-253.

Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368(21):1971- 1979. doi:10.1056/NEJMoa1213507.

Lian CG, Sholl LM, Zakka LR, et al. Novel genetic mutations in a sporadic port-wine stain. JAMA Dermatol. 2014;150(12):1336-1340. doi:10.1001/ jamadermatol.2014.1244.

Tan W, Chernova M, Gao L, et al. Sustained activation of c-Jun N-terminal and extracellular signal-regulated kinases in port-wine stain blood vessels. J Am Acad Dermatol. 2014;71(5):964-968. doi:10.1016/j.jaad.2014.07.025.

Tan W, Nadora DM, Gao L, Wang G, Mihm MC Jr, Nelson JS. The somatic GNAQ mutation (R183Q) is primarily located within the blood vessels of port wine stains. J Am Acad Dermatol. 2016;74(2):380-383. doi:10.1016/j. jaad.2015.09.063.

Lever WF, Schaumburg-Lever G, eds. Histopathology of the Skin. 7th ed. Philadelphia: J B Lippincott Co; 1990.

Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol. 1991;17(1):76-79.

Nelson JS, Milner TE, Anvari B, et al. Dynamic epidermal cooling during pulsed laser treatment of port-wine stain. A new methodology with preliminary clinical evaluation. Arch Dermatol. 1995;131(6):695-700.

Nelson JS, Milner TE, Anvari B, Tanenbaum BS, Svaasand LO, Kimel S. Dynamic epidermal cooling in conjunction with laser-induced photothermolysis of port wine stain blood vessels. Lasers Surg Med. 1996;19(2):224- 229. doi:10.1002/(sici)1096-9101(1996)19:2<224::aid-lsm15>3.0.co;2-6.

Chang CJ, Nelson JS. Cryogen spray cooling and higher fluence pulsed dye laser treatment improve port-wine stain clearance while minimizing epidermal damage. Dermatol Surg. 1999;25(10):767-772.

Chang CJ, Kelly KM, Van Gemert MJ, Nelson JS. Comparing the effectiveness of 585-nm vs 595-nm wavelength pulsed dye laser treatment of port wine stains in conjunction with cryogen spray cooling. Lasers Surg Med. 2002;31(5):352- 358. doi:10.1002/lsm.10102.

Chiu CH, Chan HH, Ho WS, Yeung CK, Nelson JS. Prospective study of pulsed dye laser in conjunction with cryogen spray cooling for treatment of port wine stains in Chinese patients. Dermatol Surg. 2003;29(9):909-915.

Waldorf HA, Alster TS, McMillan K, Kauvar AN, Geronemus RG, Nelson JS. Effect of dynamic cooling on 585-nm pulsed dye laser treatment of port-wine stain birthmarks. Dermatol Surg. 1997;23(8):657-662.

Fiskerstran EJ, Ryggen K, Norvang LT, Svaasand LO. Clinical effects of dynamic cooling during pulsed laser treatment of port-wine stains. Lasers Med Sci. 1997;12(4):320-327. doi:10.1007/bf02767154.

Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol. 2002;138(9):1149-1155.

Alster T. Laser scar revision: comparison study of 585- nm pulsed dye laser with and without intralesional corticosteroids. Dermatol Surg. 2003;29(1):25-29.

Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg. 2006;32(7):907-15. doi:10.1111/j.1524-4725.2006.32195.x.

Galbiati G, Bonfacini V, Candiani F. Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris. J Int Med Res. 1983;11 Suppl 1:31-33.

Yawalkar SJ, Macarol V, Montanari C. An overview of international clinical trials with halometasone cream. J Int Med Res. 1983;11 Suppl 1:1-7.

Schuppli R, Dressler H, Yawalkar SJ, Weirich EG. [Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate]. Z Hautkr. 1983;58(4):230-237.

The Execare Working Group. Halometasone 0.05% cream in eczematous dermatoses. J Clin Aesthet Dermatol. 2013;6(11):39-44.